Clinical trials: Phase I
Hereditary Angioedema
A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II
This study is a randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adult subjects.
- Trial name
- NCT04208412
- Testing
- KVD900
- Where
- 25 sites in United States, Austria and 8 more
- Volunteers
- 84 people
- Sponsor
- KalVista Pharmaceuticals, Ltd.
Healthy
Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults
This is a randomized, double-blind, sequential, dose-escalation, Phase 1 trial to evaluate the safety and tolerability of verdinexor. Verdinexor or placebo will be given on Days 1 and 3 to healthy adult participants.
- Trial name
- NCT02431364
- Testing
- Verdinexor
- Where
- Australia
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Karyopharm Therapeutics Inc
Myelofibrosis
Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
This is a single-center, single arm, dose finding study to assess safety and tolerability of the oral combination of Panobinostat and Ruxolitinib in patients with myelofibrosis (MF) in chronic and accelerated phase.
- Trial name
- PRIME (NCT01693601)
- Testing
- Panobinostat, Ruxolitinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- John Mascarenhas
Cerebral Palsy
A Study of UCB and MSCs in Children With CP: ACCeNT-CP
The main purpose of this study is to estimate change in motor function 12 months after treatment with a single dose of allogeneic umbilical cord blood (AlloCB) or repeated doses of umbilical cord tissue-derived mesenchymal…
- Trial name
- ACCeNT-CP (NCT03473301)
- Testing
- Infusion of allogeneic umbilical cord blood, Infusion of MSCs
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Joanne Kurtzberg, MD
Haematological Malignancies
Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies
The purpose of the study is to the evaluate safety, tolerability, pharmacokinetics (PK), and efficacy of AZD0466 as monotherapy in partciapants with advanced haematological malignancies and also to assess drug-drug interaction…
- Trial name
- NCT04865419
- Testing
- AZD0466, Voriconazole
- Where
- 15 sites in United States, Australia and 4 more
- Volunteers
- 46 people
- Sponsor
- AstraZeneca
Bone Marrow Failure Syndrome, Thalassemia
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) to determine the minimum…
- Conditions
- Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia
- Trial name
- NCT03513328
- Testing
- Thiotepa--single daily dose, Thiotepa--escalated dose
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Subarachnoid Hemorrhage, Aneurysmal
Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)
This is a phase 1/2a, randomized, double blind, single-center study comparing standard care alone to standard care with Aggrastat in patients diagnosed with aneurysmal subarachnoid hemorrhage.
- Trial name
- NCT03691727
- Testing
- tirofiban hydrochloride (AGGRASTAT®), MRI, Neurological Exam
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- David Hasan
Dry Eye, Ocular Graft vs Host Disease
Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
The objective of this study is to establish whether patients with dry eye disease (DED) are able to tolerate receiving Brimonidine: 0.15% eye drops two times a day for twelve weeks (primary tolerability objective) and to…
- Conditions
- Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
- Trial name
- NCT02975557
- Testing
- Brimonidine 0.15%, Brimonidine 0.075%
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sandeep Jain, MD
Lymphoma, T-Cell, Peripheral
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
Single arm phase I/II study of ixazomib and romidepsin in relapsed/refractory PTCL. Each cycle is 28 days. Patients will continue to receive therapy until progressive disease, unacceptable toxicity, or if any other withdrawal…
- Trial name
- NCT03547700
- Testing
- Romidepsin, Ixazomib
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Michigan Rogel Cancer Center
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Diabetes Mellitus
Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20
The purpose of the study is to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of Humalog (insulin lispro) or Humulin-R (recombinant human insulin) when administered as a single subcutaneous (SC) injection of 20 units…
- Trial name
- NCT00705536
- Testing
- Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Halozyme Therapeutics
Healthy Participants
A Study to Assess the Bioavailability of a New Tablet Formulation of Minzasolmin and the Effect of Food in Healthy Participants
The purpose of the study is to estimate the relative bioavailability of a new minzasolmin tablet formulation versus reference 'granules in capsule' formulation in healthy participants and to evaluate the effect of food with the…
- Trial name
- NCT06533475
- Testing
- Minzasolmin tablet formulation under fasting condition, Minzasolmin Granules in capsule under fasting condition, Minzasolmin tablet formulation under fed condition
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Healthy
Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate
The primary objective is to investigate the safety, tolerability and pharmacokinetics of BI 655075 following intravenous administration of single rising doses of BI 655075 when administered alone and after administration of…
- Trial name
- NCT01688830
- Testing
- Dabigatran, BI 655075
- Where
- Belgium
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Child Development, Brain Development
Baby's First Years
Recent advances in developmental neuroscience suggest that experiences early in life can have profound and enduring influences on the developing brain.
- Conditions
- Child Development, Brain Development, Household and Family Processes
- Trial name
- BFY (NCT03593356)
- Testing
- Monthly cash gift payments of $333, Monthly cash gift payments of $20
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of California, Irvine
Non-hematologic Malignancy
A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies
The purposes of this study are to evaluate the safety and tolerability of sapanisertib (MLN0128) milled active pharmaceutical ingredient (API) capsules administered both as a single agent and in combination with paclitaxel, to…
- Trial name
- NCT02412722
- Testing
- Sapanisertib, Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Myelodysplastic Syndromes
Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes
The objectives of this trial are to evaluate the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics and preliminary efficacy of volasertib in two dosing schedules of intravenous volasertib as monotherapy or in…
- Trial name
- NCT02721875
- Testing
- Volasertib, Azacitidine
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Boehringer Ingelheim
Ricin
Safety and Immunogenicity Study of Recombinant Ricin Toxin A-Chain Vaccine (RVEc™)
This study is a Phase 1, escalating, multiple-dose, single-center study to evaluate the safety and immunogenicity of the RVEc vaccine.
- Trial name
- NCT01317667
- Testing
- RVEc
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Tumors
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors
The purpose of this study is to test mirvetuximab soravtansine (IMGN853) in participants with ovarian cancer and other FOLR-1 positive tumors.
- Trial name
- IMGN853-0401 (NCT01609556)
- Testing
- Mirvetuximab soravtansine
- Where
- 12 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- ImmunoGen, Inc.
Colorectal Cancer, Ovarian Cancer
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
This is a two-part Phase 1/2 dose escalation and dose expansion study of an Adenovirus Vector (Ad5/3-D24-GMCSF), Expressing GM-CSF (GM-CSF-encoding adenovirus), ONCOS-102, in combination with anti-programmed death ligand-1…
- Conditions
- Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
- Trial name
- NCT02963831
- Testing
- ONCOS-102, Durvalumab, Cyclophosphamide
- Where
- 6 sites in United States
- Volunteers
- 67 people
- Sponsor
- Ludwig Institute for Cancer Research
Non Small Cell Lung Cancer, Secondary Lung Cancer
Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study
This is a Phase 3 study aimed at investigating the effects of a personalized exercise program (PEP) in NSCLC patients (stage I, II, IIIa) and secondary lung cancer patients undergoing surgical treatment at the University of Utah…
- Trial name
- PEP (NCT03306992)
- Testing
- Personalized Exercise Program
- Where
- United States
- Volunteers
- 182 people
- Sponsor
- University of Utah
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.